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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by a chronic 
inflammatory process, in which the pro-inflammatory cytokine Tumor Necrosis Factor (TNF)-α is 
considered to play a role. In the present study the putative involvement of TNF-α gene polymorphisms 
in pathogenesis of COPD was studied by analysis of four TNF-α gene polymorphisms in a Caucasian 
COPD population.
Methods: TNF-α gene polymorphisms at positions -376G/A, -308G/A, -238G/A, and +489G/A were 
examined in 169 Dutch COPD patients, who had a mean forced expiratory volume in one second 
(FEV1) of 37 ± 13%, and compared with a Dutch population control group of 358 subjects.
Results: The data showed that the TNF-α +489G/A genotype frequency tended to be different in 
COPD patients as compared to population controls, which was due to an enhanced frequency of the 
GA genotype. In line herewith, carriership of the minor allele was associated with enhanced risk of 
development of COPD (odds ratio = 1.9, p = 0.009). The other TNF-α gene polymorphisms studied 
revealed no discrimination between patients and controls. No differences in the examined four TNF-α
polymorphisms were found between subtypes of COPD, which were stratified for the presence of 
radiological emphysema. However, comparison of the COPD subtypes with controls showed a 
significant difference in the TNF-α +489G/A genotype in patients without radiological emphysema (χ2-
test: p < 0.025 [Bonferroni adjusted]), while no differences between COPD patients with radiological 
emphysema and controls were observed.
Conclusion: Based on the reported data, it is concluded that COPD, and especially a subgroup of 
COPD patients without radiological emphysema, is associated with TNF-α +489G/A gene 
polymorphism.
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Introduction
The pro-inflammatory cytokine Tumor Necrosis Factor 
(TNF)-α plays an important role in inflammatory processes. 
The gene coding for this cytokine is located on chromo-
some six in the class III region of the major histocompatibil-
ity complex. Several biallelic polymorphisms of this gene 
are known, including the TNF-α -308G/A gene polymor-
phism, which is the first discovered TNF-α gene polymor-
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polymorphisms. The latter gene polymorphisms are located 
in the promoter region of the gene, whereas another gene 
polymorphism found at position +489G/A, is located in the 
first intron of the gene [1–3].
Several studies have analyzed the relationship between 
TNF-α gene polymorphism and disease. Carriage of the 
TNF-α -308A allele was found to be associated with dis-
eases such as melioidosis [4] mucocutaneous leishmania-
sis [5] and cerebral malaria [6], although no association 
could be demonstrated with other disorders like meningo-
coccal disease [7] and rheumatoid arthritis (RA) [8]. Con-
tradictory results are reported on the relationship between 
TNF-α -308G/A polymorphism and asthma. Several stud-
ies found an association of this disease with the TNF-α -
308 minor allele [9,10], whereas Albuquerque and col-
leagues reported an association of the TNF-α -308 com-
mon allele with childhood asthma [11]. Moreover, Louis et 
al failed to show any relationship between the TNF-α -
308G/A polymorphism and asthma [12].
Concerning the TNF-α -238G/A polymorphism, a higher 
frequency of the A allele was shown in multiple sclerosis 
[13], and alcoholic liver disease [14], whereas others re-
ported no association with Chagas' disease [15] and coal 
workers pneumoconiosis [16]. The TNF-α -376G/A gene 
polymorphism was reported to be an independent risk fac-
tor for the development of cerebral malaria [17], whereas 
this polymorphism was not associated with autoimmune 
diseases like RA [18]. Finally, a limited number of studies 
have examined the TNF-α +489G/A polymorphism, show-
ing an association with prostate cancer, and with a sub-
group of common variable immune deficiency patients with 
granulomata [19,20]. In contrast, a lower frequency of the 
minor allele was reported in RA patients, whereas in pa-
tients with idiopathic pulmonary fibrosis no association with 
TNF-α +489G/A polymorphism was observed [21,22].
In order to study the functionality of the TNF-α gene poly-
morphisms, in vitro studies have been performed. Some of 
those studies showed that cell lines with the minor TNF-α -
308A allele produced more TNF-α compared with the cell 
lines carrying the -308G allele [23,24], whereas other au-
thors studying the relation between TNF-α production and 
TNF-α gene polymorphisms at position -862C/A, -856C/T, 
-574G/A, -308G/A, -238G/A and +70(addition of C) failed 
to show an association [13,25,26]. Therefore, it appears 
that the relationship between TNF-α gene polymorphism 
and TNF-α production is yet unresolved.
Chronic inflammation is generally accepted as a character-
istic finding in COPD patients, and is considered to con-
tribute to pathology. Enhanced levels of TNF-α have been 
detected in sputum [27] and in circulation [28] of COPD 
patients, indicating that this cytokine is involved in both the 
local and systemic inflammation present in COPD. Analysis 
of possible TNF-α gene polymorphisms in COPD could be 
related to a higher susceptibility to develop this disabling 
pathological condition. Previously, a relationship between 
COPD and TNF-α -308G/A polymorphisms was reported 
in a Taiwanese [29] and a Japanese population [30]. Re-
cent studies with Caucasian COPD populations did not 
support these data [31–33], although it has been suggest-
ed that homozygosity for the A allele predisposes for a 
worse prognosis in COPD [33]. In the present study the 
putative involvement of TNF-α gene polymorphisms in rela-
tion to COPD was extended by analysis of these polymor-
phisms at locations -376G/A, -308G/A, -238G/A and 
+489G/A, which are so far the most studied polymor-
phisms, and were reported, as described above, to be as-
sociated with certain diseases. The study was performed in 
a Caucasian COPD population, stratified for the presence 
of radiological emphysema based on high resolution com-
puted tomography (HRCT) scanning.
Materials and Methods
Study Population and Control Population
The patient group consisted of 169 Caucasian Dutch 
COPD patients admitted to a pulmonary rehabilitation 
center (Horn, The Netherlands). The diagnosis of COPD 
was made according to the criteria of the American Thorac-
ic Society [34]. The forced expiratory volume in one second 
(FEV1) had to be less than 70% of the reference value, and 
the increase in FEV1 after inhalation of a β2-agonist less 
than 10% of the reference value. Patients with α1-antit-
rypsin deficiency, and patients with bronchial asthma were 
excluded from the study.
358 random healthy Dutch Caucasian donors from the De-
partment of Immunohaematology and Blood Transfusion 
(Leiden, The Netherlands) were used as a population con-
trol group. Although recruited from different parts of The 
Netherlands, population stratification is unlikely to be an is-
sue because of the small size of this country.
The local ethical review committee approved the research 
program, and informed consent was obtained.
DNA Isolation and TNF-α gene Polymorphism Typing
The four TNF-α gene polymorphisms located on positions 
-376G/A, -308G/A, -238G/A and +489G/A, relative to the 
transcriptional start site of the TNF-α gene, were detected 
in genomic DNA derived from peripheral blood leukocytes, 
as described previously [13,35]. In short, fragments of the 
TNF-α promoter gene were amplified by PCR using primer 
'C', spanning -164/-144 (5'-TCTCGGTTTCTTCTC-
CATCG-3') and primer 'D' spanning -675/-655 (5'-
GAGTCTCCGGGTCAGAATGA-3'). The amplified DNA 
segments were analysed by dot blot analysis using specific Page 2 of 7
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three polymorphisms in the promoter region. To type for 
TNF-α +489G/A polymorphism a PCR product was gener-
ated using primer 'A' spanning +48/+67 (5'-GGAGA-
GAAGCAACTACAGAC-3') and primer 'B' spanning 
+598/+579 (5'-CACACTTAGTGAGCACCTTC-3'). PCR 
products were digested with Tai I (MBI Fermentas, St. 
Leon-Rot, Germany) and size separated on 1.2% agarose 
gel. In the PCR product derived from individuals carrying 
the normal allele two Tai I restriction sites are present, giv-
ing rise to fragments of 111, 159 and 281 bp. The +489 G 
to A substitution leads to loss of one Tai I restriction site re-
sulting into the formation of two fragments of 159 and 392 
bp after digestion.
Computed Tomography (CT) Emphysema Score
In all patients evaluation of the presence and severity of pa-
renchymal destruction, the hallmark of emphysema, was 
performed by HRCT using a commercial scan (Somatom 
Plus; Siemens, Erlangen, Germany). For both the right and 
the left lung, five thin-section HRCT scans were obtained 
at full inspiration with the patient in supine position. Two 
scans of the upper zones were made at 3 cm and 6 cm 
above the carina, two scans of the lower zones at 3 cm and 
6 cm below the carina, and one at the level of the carina. 
Scanning parameters were 1.0mm collimation, 137 kVp, 
220 mA, 1.0 second scanning time, and high-resolution re-
construction algorithm (level B800 HU; width: 1600). The 
grade of radiological emphysema was assessed by visual 
CT emphysema score according to Sakai et al. [36], which 
is based on the assessment of two aspects of emphysema: 
severity and extent. Severity was graded on a 4-point scale: 
0, no emphysema; 1, low attenuation areas < 5 mm in di-
ameter; 2, circumscribed low attenuation areas > 5 mm in 
addition to those < 5 mm; 3, diffuse low attenuation areas 
without normal intervening lung. The extent of emphysema 
was on a 4-point scale: 1, < 25% of the lung parenchyma 
involved; 2, 25–50% involvement; 3, 50–75% involvement; 
4, > 75% involvement. For each of the ten lung fields, the 
score for severity (4-point scale ranging from 0–3) was 
multiplied by that for extent (4-point scale ranging from 1–
4) to give a degree of radiological emphysema score. The 
score for the ten lung fields were summed. The potential 
maximal score for each patient was 120. A CT emphysema 
score of < 30 is considered as having limited or no radio-
logical emphysema [37]. All patients with radiological em-
physema (CT score > 30) were taken together and they 
were compared with the group considered as having no ra-
diological emphysema (CT score < 30).
Pulmonary Function
Lung function was measured by an experienced lung func-
tion technician using a pneumotachometer (Jaeger 7, 
Würzburg, Germany). All measurements were performed 
according to the European Respiratory Society recommen-
dations [38]. The highest value from at least three techni-
cally acceptable spirometric manoeuvres was used.
Statistical Analysis
Data are presented as mean ± standard deviation (SD). The 
Mann-Whitney U test was used for differences in age and 
FEV1 between groups. The χ2-test was used to detect sig-
nificant differences in genotype frequencies and sex. A 
Bonferroni correction was applied in multiple comparisons 
between study groups. Odds ratios (OR) with 95% confi-
dence interval (CI) were calculated to estimate the poten-
tial risk for developing COPD among carriers (GA) versus 
non-carriers (GG) of the minor allele (uncorrected p; Fisher 
exact when needed). P-values smaller than 0.05 were taken 
as significantly different. In case of performing the Bonfer-
roni correction, statistical significance was defined as p < 
0.05/k, where k is the number of parameters for the Bonfer-
roni correction in each set of comparisons. The data were 
analysed with the Statistical Package for the Social 
Sciences 10.0 computer program (SPSS Inc., Chicago, IL)
Results
Characteristics of the COPD populations
A Caucasian population of 169 Dutch COPD patients was 
studied (mean age 66 ± 8 years, range between 39–88 
years). Male COPD patients constituted 65% of the COPD 
population. The spirometric data indicated that the patients 
suffered from severe airflow limitation (FEV1 predicted: 
mean 37 ± 13%, range 14–69%). Forty-nine patients 
(29%) were current smokers, 115 patients (68%) were ex-
smokers and only 5 patients (3%) indicated that they had 
never smoked. The mean number of pack years of the cur-
rent and ex-smokers was 33 ± 19 years (range 2–90). 
Maintenance treatment of the patients consisted in general 
of inhalation corticosteroids, β2-agonists and anticholiner-
gics (ipratropium bromide). Oral corticosteroids were pre-
scribed in 60% of the patients and oral theophylline in 
55%. Continuous oxygen was used by 20% of the patients.
The population control group consisted of 358 random 
healthy Dutch Caucasian subjects derived from an anony-
mous panel of blood donors, with a mean age of 40 ± 17 
years (p < 0.025 [Bonferroni adjusted] as compared to 
COPD population). Fifty seven percent of the controls were 
males, which was not different from the patient population 
(p = 0.1). No further characteristics of this population con-
trol group were available.
TNF-α gene polymorphism and susceptibility to develop 
COPD
The genotype frequencies of four TNF-α gene polymor-
phisms in the COPD population were compared with those 
in control subjects in order to assess differences between 
the two groups (Table 1). In both the patient and the control 
groups the alleles at the individual loci of the TNF-α gene Page 3 of 7
(page number not for citation purposes)
Respiratory Research   Vol 3 No 1   Küçükaycan et al.were in Hardy-Weinberg equilibrium, with non-significant 
χ2-values (data not shown). For TNF-α +489G/A gene pol-
ymorphism, a tendency for a difference in genotype fre-
quency between COPD patients and controls was 
observed (p = 0.019), which was due to enhanced GA fre-
quency in the patient group. No differences were obtained 
for the three other polymorphisms tested at TNF-α gene lo-
cus position -376G/A, -308G/A and -238G/A. Since the 
control group was younger than the patient population, as 
reported above, the TNF-α +489G/A genotype frequency 
in the COPD patients was also compared with a subgroup 
of the control subjects of forty years and older (n = 165, 
age 53 ± 9 years), which revealed a significant difference 
(p = 0.011). Next the association between carriership of 
the TNF-α +489A allele and susceptibility to develop 
COPD was analysed using the whole population control 
group. This analysis revealed that carriers (GA) had twice 
the risk of developing COPD as compared to non-carriers 
(GG) (OR = 1.9 [95% CI = 1.2-3.1; p = 0.009]), which 
strengthens the above reported observations.
In order to analyse whether subtypes of COPD were relat-
ed to TNF-α gene polymorphism, the COPD population 
was stratified for the presence of radiological emphysema 
based on HRCT scanning (Table 2). In 32 (20%) out of the 
159 patients who underwent HRCT, no radiological em-
physema could be detected, whereas in 80% of the pa-
tients radiological emphysema was present. Both 
subgroups of patients did not differ in age or sex. However, 
FEV1% predicted was significantly lower in the patients 
with radiological emphysema as compared to the subgroup 
without radiological emphysema. Strikingly, four out of the 
five patients who had never smoked were part of the sub-
group without radiological emphysema, representing 
12.5% of the patients. In contrast, only one of the 127 pa-
tients with radiological emphysema had never smoked (χ2-
test, p < 0.01 [Bonferroni adjusted]). In addition, the mean 
pack years tended to be higher in the subgroup of patients 
with emphysema.
No significant differences were observed between the sub-
groups of patients concerning TNF-α polymorphisms at po-
sition -376G/A (p = 0.477), -308G/A (p = 0.334), -238G/
A (p = 0.207), and +489G/A (p = 0.184). However, as 
shown in Table 3, comparison of TNF-α +489G/A geno-
type between patients without radiological emphysema 
and population controls revealed a significant difference (p 
= 0.004, thus p < 0.025 [Bonferroni adjusted]), whereas 
no difference between control subjects and patients with 
radiological emphysema was observed (p = 0.131). In line 
herewith, analyses of the contribution of the TNF-α +489A 
allele (via comparison of GA genotype versus GG geno-
type) in the risk of the development of COPD revealed an 
OR of 3.6 (95% CI = 1.6 - 8.1; p = 0.003) in the subgroup 
of patients without radiological emphysema, while analysis 
of the COPD patients with radiological emphysema and 
controls revealed an OR of 1.7 (95% CI = 0.97 - 2.8; p = 
0.064).
Table 1 
Genotype frequencies of TNF-α -376G/A, -308G/A, -238G/A and +489G/A gene polymorphisms in COPD patients and population con-
trol group*
Genotype COPD Control P-value †
TNF -376G/A
GG 162 (98) 306 (99)
GA 3 (2) 3 (1) 0.562
AA 0 (0) 1 (0)
TNF -308G/A
GG 113 (69) 237 (71)
GA 49 (30) 91 (27) 0.397
AA 1 (1) 7 (2)
TNF -238G/A
GG 151 (92) 310 (94)
GA 13 (8) 20 (6) 0.544
AA 0 (0) 1 (0)
TNF +489G/A
GG 118 (75) 264 (84)
GA 38 (24) 45 (14) 0.019
AA 1 (1) 6 (2)
* Values are expressed as absolute numbers; percentages are given in parentheses. For technical reasons, not all the samples were successfully 
genotyped. † The χ2-test of the genotype frequencies of TNF-α -376G/A, -308G/A, -238G/A, and +489G/A gene polymorphisms. Statistical sig-
nificance was defined as p < 0.0125 using Bonferroni correctionPage 4 of 7
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The present study describes the relation between COPD 
and four TNF-α gene polymorphisms in a Dutch Caucasian 
population. The data showed that the TNF-α +489G/A 
genotype frequency tended to be different in COPD pa-
tients compared with a population control group, while no 
significant differences could be demonstrated in the TNF-α
gene at position -376G/A, -308G/A, and -238G/A. Since 
the population control group was younger than the COPD 
population, a subgroup of control subjects of forty years 
and older was selected, and analysis revealed significant 
differences in TNF-α +489G/A genotype frequency as 
compared with COPD patients. Moreover, carriership of 
the TNF-α +489A allele was associated with enhanced risk 
of developing COPD (OR = 1.9). The higher frequency of 
TNF-α +489G/A polymorphism in the COPD population 
could be related to an increased percentage of individuals 
with TNF-α +489 GA genotype, compared with healthy 
controls, whereas frequency of the +489 AA was too low 
(1% in patients versus 2% in controls) to allow meaningful 
comparisons. Based upon HRCT score, a technique that 
has generally been accepted to detect emphysema accu-
rately at relatively early stage, and to allow objective meas-
urements of the degree of abnormality [37,39], patients 
were divided in those with and without radiological emphy-
sema. Since HRCT does not detect microscopic emphyse-
ma, it cannot be excluded that patients classified as having 
no radiological emphysema, could have microscopic em-
physema. This indicates that in this study patients with 
more severe emphysema (diagnosed by the presence of ra-
diological emphysema) were compared with patients with 
less severe or no emphysema (diagnosed by the absence 
of radiological emphysema), which is also supported by the 
observed differences in FEV1 in both subgroups. The dif-
ferences in TNF-α +489G/A polymorphism seem to be re-
lated to a higher prevalence of this polymorphism in the 
subgroup of patients without radiological emphysema. In-
terestingly, four out of the 32 (12.5%) patients from this 
subgroup had never smoked. Of those four patients three 
exhibited the heterozygote genotype (data not shown). 
These data strongly suggest TNF-α +489G/A polymor-
phism as a risk factor for COPD. Further studies have to be 
performed to confirm this observation, analysing large pan-
els of patients with smoking and non-smoking related 
COPD. In addition, the use of a control population of more 
comparable age and for whom smoking data was available 
would further enhance the strength of these kinds of stud-
ies.
The gene polymorphism of TNF-α +489G/A was de-
scribed for the first time in 1996 and is located in the first 
intron of the gene [3]. Till now, limited numbers of studies 
have examined a possible relationship between this poly-
morphism and pathologic conditions. In patients with pros-
tate cancer an increased incidence of TNF-α +489 GA 
genotype was reported, implicating that changes at TNF-α
+489G/A may be involved in oncogenesis of prostate can-
cer [19]. Furthermore, the minor TNF +489A allele was as-
sociated with a subgroup of common variable immune 
deficiency patients with granulomata [20]. Contrary to 
these studies, and to the present findings in COPD, a sig-
nificantly lower frequency of the TNF-α +489 GA and TNF-
α +489 AA genotypes was reported in RA patients as com-
pared with controls. Those RA patients carrying the minor 
+489A allele also showed a less severe course [21]. Fur-
thermore, in patients with idiopathic pulmonary fibrosis no 
association with TNF-α +489G/A polymorphism was ob-
served [22]. Therefore, further research is needed to eluci-
date the impact of this TNF-α gene polymorphism on 
susceptibility and severity of inflammatory diseases.
Recently, Kaijzel et al investigated the functional conse-
quence of the +489G/A polymorphism, by analysing the 
contribution of distinct TNF-α alleles in TNF pre-mRNA pro-
duction. No difference could be detected between the dif-
ferent alleles in TNF-α pre-mRNA yield upon in vitro and 
Table 2 
Clinical characteristics of subgroups of COPD patients without and with radiological emphysema *
Patients without radiological emphysema Patients with radiological emphysema
(n = 32) (n = 127) P-value †
Age (year) 66 ± 8 66 ± 8 0.70
Sex (male/female) 16/16 86/41 0.062
FEV1% predicted 46 ± 15 35 ± 11 0.001
Smoking behavior
-never smoked/(ex)-smoker 4/28 1/126 0.001
-pack years 26 ± 22 34 ± 18 0.037
* Values are expressed as mean ± SD or as absolute numbers. † The Mann-Whitney U test was used for differences in age and FEV1 between 
groups. The χ2-test was used to detect significant differences in genotype frequencies and sex. Statistical significance was defined as p < 0.01 
using Bonferroni correction.Page 5 of 7
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and RA patients [35]. Therefore, no indications for a func-
tional significance for this particular TNF-α gene variant 
have been demonstrated so far. In general, an association 
between a specific disease and an allele can be interpreted 
either as a causal relation or as a linkage disequilibrium be-
tween the allele and a nearby gene or a set of genes in-
volved in the pathophysiology of that disease. The question 
of whether the minor TNF-α +489A allele itself is related to 
a higher susceptibility for developing COPD or that the al-
lele has a linkage disequilibrium with a nearby causal gene 
also remains to be determined. The TNF gene is located in 
the class III region of the MHC, on chromosome 6p. In this 
region several genes are present that encode for proteins 
involved in immune and inflammatory responses, which 
could therefore be potential candidates to be studied. 
These genes include the complement system proteins C2, 
C4 and Factor B, lymphotoxin (LT) α and β, as well as mem-
bers of the 70 kDa heat shock protein (hsp70) family [40]. 
As well as studying single nucleotide polymorphisms, ex-
tended haplotypes of genes in this region should also be 
analysed, since it is unlikely that only one gene locus is re-
sponsible for predisposition to and clinical outcome of the 
disease. The only TNF-α gene polymorphism that has been 
examined in COPD is the TNF-α gene polymorphism on lo-
cation -308G/A. In line with our data, studies in Caucasian 
populations showed no association between COPD and 
TNF-α -308G/A polymorphism [31–33]. However, Keat-
ings et al, showed that homozygosity for the A allele predis-
poses to a worse prognosis for COPD, implicating that an 
increase in A allele in the COPD group may have been 
missed due to survival bias in the GA and GG groups [33]. 
In contrast to these studies on white subjects, two studies 
on Asian subjects showed an association at TNF-α -308G/
A polymorphism between COPD patients and population 
controls [29,30]. The possible cause for this discrepancy 
may be an ethnic difference affecting prevalence. The TNF-
α-308A allele frequency ranged from 10% [32] to 17% 
[31] in the white population, and from 5% [29] to 8% [30] 
in the Asian population. Alternatively, the allele could be in 
linkage disequilibria with another gene that increases sus-
ceptibility to COPD in smokers only in the Asian population.
The allele frequencies as reported in our study of TNF-α -
376A (1% in both study groups), TNF-α -238A (3% and 
4% in controls and COPD respectively), and TNF-α +489A 
(12% and 9% respectively in controls and COPD) are in 
agreement with other studies analyzing Caucasian popula-
tions [3,13,18,22]. However, due to the fact that the un-
common allele at gene loci -376 and -238 is very rare, we 
cannot exclude the possibility of a type II error (the study 
population was too small to detect a difference).
Conclusion
In conclusion, from the present study it is established that 
the TNF-α +489G/A gene polymorphism is associated 
with COPD, especially in a subgroup of patients without ra-
diological emphysema. In contrast, the genotype frequen-
cies of TNF-α -376G/A, -308G/A and -238G/A gene 
polymorphisms in the COPD population were not different 
from a population control group. The impact of this TNF-α
+489G/A gene polymorphism in relation to susceptibility of 
COPD and impact on the inflammatory processes in 
COPD needs to be explored.
Abbreviations
A = Adenine, bp = base pairs, CI = confidence interval, COPD = chron-
ic obstructive pulmonary disease, FEV1 = forced expiratory volume in 
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